Prostate Cancer Therapeutics Market To Reach $39.0 Billion by 2033

Prostate Cancer Therapeutics Market Growth & Trends

The global prostate cancer therapeutics market size is expected to reach USD 39.0 billion by 2033, registering a CAGR of 8.8% from 2026 to 2033, according to a new report by Grand View Research, Inc. The growth of the market is attributed to the escalating prevalence of prostate cancer which in turn increases the demand for novel therapeutics. For instance, as per the ACS in 2022, prostate cancer is expected to have 268,490 new cases and lead to the death of 34,500 people worldwide. It affects roughly one out of every eight men at some point in their lives and is more common in older men.

A surge in government funding and increased public and private sector initiatives to enhance knowledge, and awareness about the availability of medicines amongst the public are projected to accelerate market growth. Furthermore, a rising preference for online drug purchasing over traditional methods, an increase in the number of internet users, and a rise in awareness regarding online pharmacies are expected to enhance the treatment adoption rate.

As per the American Cancer Society, in 2022, prostate cancer is the second leading cause of death in the male population of the U.S. Around one man in every 41 dies from prostate cancer. Although prostate cancer is a deadly disease, the mortality rate from the disease is low. The availability of a supportive regulatory landscape is expected to drive the adoption of novel products such as 177Lu-PSMA-617, which is precision medicine for patients that have not been cured with multiple rounds of treatment. The product received FDA approval in March 2022 for the treatment of mCRPC.

Targeted and biological therapy, chemotherapy, and hormonal therapy are some of the methods used to treat the condition. The high cost of targeted therapies and other immunotherapies is projected to act as a significant limitation on the global market. Low awareness of technological advancements in the therapeutic area in developing countries is expected to become a restrain for the market.

New trials are being conducted by institutes such as MRC Clinical Trials Unit at UCL. A June 2022, publication by the institute highlights secondary cancer tumor type of prostate cancer patients are benefited more from the use of chemotherapy such as docetaxel with an enhanced survival rate of 39%. These studies are creating a more effective way of providing a personalized medicine approach to prostate cancer patients so that they experience fewer side effects.

 Request a free sample copy or view report summary: Prostate Cancer Therapeutics Market Report

Prostate Cancer Therapeutics Market Report Highlights

• Based on drug class, the hormonal therapy segment dominated the market with the largest revenue share of 81.5% in 2025, driven by its established role in managing advanced prostate cancer. Androgen deprivation remains a core part of treatment across advanced diseases.

• Based on distribution channel, the hospital pharmacies segment dominated the market with the largest revenue share of 57.3% in 2025, supported by the use of prescription-based prostate cancer therapies within hospital-led treatment. Hospital pharmacies provide direct access to medicines used under specialist supervision.

• North America dominates the prostate cancer therapeutics market in 2025 with a market share of 53.3%, driven by a large diagnosed patient population and broad use of prostate cancer medicines. The U.S. accounts for a major portion of regional treatment demand.

Prostate Cancer Therapeutics Market Segmentation

Grand View Research has segmented the global prostate cancer therapeutics market based on drug class, distribution channel, and region:

Prostate Cancer Therapeutics Drug Class Outlook (Revenue, USD Billion, 2021 - 2033)

• Hormonal Therapy

• Chemotherapy

• Immunotherapy

• Targeted Therapy

• Others

Prostate Cancer Therapeutics Distribution Channel Outlook (Revenue, USD Billion, 2021 - 2033)

• Hospital Pharmacies

• Drug Stores & Retail Pharmacies

• Online Pharmacies

Prostate Cancer Therapeutics Regional Outlook (Revenue, USD Billion, 2021 - 2033)

• North America

  • U.S.

  • Canada

  • Mexico

• Europe

  • UK

  • Germany

  • France

  • Italy

  • Spain

  • Denmark

  • Sweden

  • Norway

• Asia Pacific

  • Japan

  • China

  • India

  • Australia

  • South Korea

  • Thailand

• Latin America

  • Brazil

  • Argentina

• Middle East & Africa

  • South Africa

  • Saudi Arabia

  • UAE

  • Kuwait

List Of Key Players Prostate Cancer Therapeutics Market

• Johnson & Johnson Services, Inc.

• Astellas Pharma Inc.

• Pfizer Inc.

• Bayer AG

• AstraZeneca

• Sanofi

• Ipsen Pharma

• Ferring Pharmaceuticals

• Sumitomo Pharma Co., Ltd.

• AbbVie Inc.